RecruitingPhase 2NCT05504291
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Studying Hereditary retinoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Rachana ShahChildren's Oncology Group
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (20)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Children's Hospital Medical Center of Akron, Akron, Ohio, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Dell Children's Medical Center of Central Texas, Austin, Texas, United States
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05504291 on ClinicalTrials.govOther trials for Hereditary retinoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06725173Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.University of Washington
- RECRUITINGEARLY PHASE1NCT06972602High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous SeedEye & ENT Hospital of Fudan University
- RECRUITINGPHASE2NCT06679634Retinoblastoma Phase II Expanded Access Clinical TrialTargeted Therapy Technologies, LLC
- RECRUITINGEARLY PHASE1NCT06424301Targeting NUDT21 siRNA Drugs for Patients With Refractory RetinoblastomaEye & ENT Hospital of Fudan University
- RECRUITINGNCT06367530Trilateral Retinoblastoma: Incidence and OutcomesAmsterdam UMC, location VUmc
- ENROLLING BY INVITATIONNCT06227962Cognitive Functioning and Health Related Quality of Life in Retinoblastoma SurvivorsAmsterdam University Medical Center
- RECRUITINGPHASE2, PHASE3NCT04681417Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual OutcomeInstitut Curie
- RECRUITINGPHASE3NCT04799002Topotecan and Melphalan for RetinoblastomaSun Yat-sen University